<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117608">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831869</url>
  </required_header>
  <id_info>
    <org_study_id>2012GSF11824</org_study_id>
    <nct_id>NCT01831869</nct_id>
  </id_info>
  <brief_title>Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism</brief_title>
  <official_title>The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subclinical hypothyroidism (SCH) is a common condition affecting 3-10% of the general
      population, especially in women older than 50 years old. It is controversial whether SCH can
      lead to increased risks of cardiovascular (CV) disease and whether treatment with
      L-thyroxine reverses these risks. The present study was designed to evaluate the effect of
      L-thyroxine treatment in SCH on lipid profile, atherosclerosis, endothelial function, serum
      inflammatory factors and adipocytokines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in lipid profile</measure>
    <time_frame>measured at baseline; 6 month; 12 months and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>change in thickness of blood vessel wall</measure>
    <time_frame>measured at baseline; 6 months; 12 months and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in endothelial function</measure>
    <time_frame>measured at baseline; 6 months; 12 months and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of adipocytokines</measure>
    <time_frame>measured at baseline; 6 months; 12 months and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oxidative Stress and Chronic Inflammatory Factors Related with Atherosclerosis</measure>
    <time_frame>measured at baseline; 6 months; 12 months and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Thyroid Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>L-thyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration, starting dose 25 or 50 micrograms once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-thyroxine</intervention_name>
    <arm_group_label>L-thyroxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged of 18 to 60 years old;

          -  Diagnosis was subclinical hypothyroidism(elevated serum thyroid-stimulating hormone
             levels with normal serum free T4 levels measured at least two times with a
             three-month interval);

          -  untreated.

        Exclusion Criteria:

          -  Pregnancy or lactation women;

          -  Presence of pituitary/hypothalamic disorders, diabetes mellitus or other endocrinal
             and metabolic disorders;

          -  Presence of psychological or physical disabilities,acute infection, cerebrovascular
             or cardiovascular disease, chronic respiratory disease and other illnesses known to
             alter lipid metabolism;

          -  Taking lipid-lowering agents and other drugs that known to influence thyroid
             function, blood pressure, heart function or bile acids;

          -  Obviously poor compliance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiajun Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Gao</last_name>
    <phone>+86 53168776910</phone>
    <email>gaoling1@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanshan Shao</last_name>
      <phone>86-531-68776094</phone>
      <email>shaoshanshan11@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 1, 2013</lastchanged_date>
  <firstreceived_date>April 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Ling Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Subclinical hypothyroidism</keyword>
  <keyword>L-thyroxine</keyword>
  <keyword>Lipid</keyword>
  <keyword>endothelial function</keyword>
  <keyword>inflammatory factor</keyword>
  <keyword>adipocytokine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
